Pharmaceutical grade chondroitin sulfate: Structural analysis and identification of contaminants in different commercial preparations  by da Cunha, André Luiz et al.
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a  b  s  t  r  a  c  t
The  aim  of  the present  study  was  to  characterize  16 pharmaceutical  grade  chondroitin  sulfate  (CS)  sam-
ples,  concerning  the  structure  and presence  of  contaminants,  in  comparison  to USP  and  analytical  grade
CS. Agarose  gel  electrophoresis  has shown  that  only  5 samples  were  >90%  CS,  while  11  contained  less
than  15%  CS.  FACE  (ﬂuorophore-assisted  carbohydrate  electrophoresis)  revealed  that  maltodextrin  was
the main  contaminant  in  nine  of them,  and  lactose  in  two.  Raman  spectroscopy  corroborated  these  results.
Concerning  the  structure  of the CS  present  in the  ﬁve  CS-rich  samples,  the  ratios  4-sulfated:6-sulfatedeywords:
hondroitin sulfate
ACE
aman spectroscopy
ontaminants
altodextrin
actose
disaccharides  varied  from  0.9 to  1.7,  and  their modal  molecular  weight  was  20–29  kDa.  Also,  they were
all  contaminated  by small  amounts  of  keratan  sulfate  (<1%).  In  conclusion,  our ﬁndings  indicate  that  the
composition  of  CS  preparations  not  always  corresponds  to the  manufacturers’  descriptions,  and  indicate
that  further  characterization  should  be  required  for the  registry  and  license  of  pharmaceutical  grade  CS.
©  2015  Elsevier  Ltd.  All  rights  reserved.. Introduction
Osteoarthritis is a major public health problem for which there
re few effective medical remedies. In the 1990s, chondroitin sul-
ate (CS) and glucosamine (GlcN) were introduced as “nutraceutical
gents” for treatment of osteoarthritis (Reginster, Gillot, Bruyere,
 Henrotin, 2000), and soon it was shown that these compounds
lso present anti-inﬂammatory and chondroprotective activities
Iovu, Dumais, & du Souich, 2008; Vallières & du Souich, 2010).
ecause they are extracted from natural sources, and due to their
afety, treatment with CS and GlcN acquired substantial popularity.
hey are absorbed from the gastrointestinal tract (Ronca, Palmieri,
anicucci, & Ronca, 1998), and are excreted in the urine, part as
ntact polymers and part as partial degradation products (Baccarin,
achado, Lopes-Moraes, Vieira, & Michelacci, 2012; Michelacci,
oim, Bergamaschi, Rovigatti, & Schor, 1992), indicating their sys-
emic distribution. Furthermore, they were tested in a number of
linical trials, which demonstrated their efﬁcacy in osteoarthritis
review in McAlindon, LaValley, Gulin, & Felson, 2000).
∗ Corresponding author at: Instituto de Ciências Biológicas, UFJF, Brazil.
E-mail address: jair.aguiar@ufjf.edu.br (J.A.K. de Aguiar).
ttp://dx.doi.org/10.1016/j.carbpol.2015.08.006
144-8617/© 2015 Elsevier Ltd. All rights reserved.CS and GlcN are currently recommended by The European
League Against Rheumatism (EULAR) as a “SYSADOA” – symp-
tomatic slow-acting drug for the treatment of osteoarthritis. It
means that they provide pain relief and increased joint mobility
only after a relatively long period of regular administration (1–2
months), despite the fact that their effects last long after the end of
treatment (2–3 months).
It is well established that CSs are composed of alter-
nating 1,3-N-acetyl--d-galactosamine and 1,4--d-glucuronic
acid units, which bear 4-O- and/or 6-O-sulfations at the N-
acetylgalactosamine units. Most CS polymers are hybrid structures,
composed of two  or more types of disaccharide units, disposed in
speciﬁc patterns (Michelacci & Dietrich, 1976, 1986). Depending
on the disaccharide unit that predominates, CS receive different
names, and may  have different biological activities. For instance,
it was shown that the CS of human adult articular cartilage is
predominantly 6-sulfated, while in human growth cartilage it is
50% 4-sulfated and 50% 6-sulfated (Michelacci, Mourão, Laredo, &
Dietrich, 1979). The distribution of these units in the polymer is
very speciﬁc and well deﬁned.In fact, some authors report that CS has little symptom-
modifying activities (Distler & Anguelouch, 2006), while others
include CS in the guidelines for osteoarthritis treatment (Cutolo,
Berenbaum, Hochberg, Punzi, & Reginster, 2015). These different
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Midura, 2000). The mercuric ion was removed by addition of 30 L
of a 50% slurry of Dowex H+ resin, which was  removed by ﬁltrationA.L. Cunha et al. / Carbohydr
ctivities described by different authors could be due either to dif-
erences in the CS structures or to the presence of contaminants (or
oth).
CSs are isolated and puriﬁed from animal sources and, as already
entioned, have complex structures. Hence, it is very important to
nsure the quality of the pharmaceutical grade CSs commercially
vailable, which are currently used as raw materials by compound-
ng pharmacies to prepare remedies to ﬁt the unique need of each
atient. Thus, the ﬁrst aim of this study was to analyze the structure
f the pharmaceutical grade CSs available in local compounding
harmacies (Juiz de Fora, MG,  Brazil).
These compounds were submitted to agarose gel electrophore-
is, which has shown that 11, out of 16 samples, contained much
ess CS than declared by their respective “Certiﬁcates of Analysis”.
onsequently, our second aim was to identify the main contami-
ants. Fluorophore-assisted carbohydrate electrophoresis (FACE),
aman spectroscopy, immunoblotting, and paper chromatography
ere used to identify the main contaminants.
FACE is a method introduced in 1990 for the analysis of the car-
ohydrate moiety of glycoconjugates (Jackson, 1990). This method
s based on the separation, by polyacrylamide gel electrophoresis,
f saccharides that have been labeled with a suitable ﬂuorophore.
n principle, carbohydrates that have a reducing aldehydic car-
on are reacted with a ﬂuorophore that has a primary amino
roup. The resulting Schiff base is stabilized by reductive amination
ith sodium cyanoborohydride forming the stable ﬂuorescently
abeled derivatives, which are separated by high resolution
AGE.
Raman spectroscopy is a vibrational technique based on scat-
ered radiation, which has been successfully applied to investigate
tructure of different carbohydrates (Almeida et al., 2010; Mainreck
t al., 2012). It has been applied to the analysis of both sulfated and
on-sulfated polysaccharides, including heparin (Beni, Limtiaco, &
arive, 2011). It is a non-destructive technique that requires small
mount of sample and is not time consuming. In the present study,
aman spectroscopy was used to conﬁrm the identiﬁcation of CS
nd contaminants.
Immunoblotting was used to identify keratan sulfate, and paper
hromatography to identify and quantify inorganic sulfate.
. Experimental
.1. Materials
Sixteen samples of pharmaceutical grade CS raw material were
btained from seven pharmaceutical dealers in Juiz de Fora, MG,
razil. These samples were numbered – samples #1–16 – and,
ccording to the “Certiﬁcate of Analysis” of each product, all are
xtracted from bovine trachea. These samples came from the fol-
owing countries: sample #6 from Brazil; samples #1, 2, 5, 7, 8, 9,
0, 11, and 14 from USA; samples #3, 4, 12 and 16 from China; and
amples #13, and 15 from Germany.
United States Pharmacopeia standard CS (USP-CS) was obtained
rom the United States Pharmacopeia (Rockville, MD; cat. 1133570,
ot H1K241). Analytical grade chondroitin 4-sulfate (Ch4S, from
ovine trachea), chondroitin 6-sulfate (Ch6S, from shark cartilage),
ermatan sulfate (DS, from porcine mucosa), maltodextrin, lac-
ose, and sodium sulfate were purchased from Sigma–Aldrich Co
St. Louis, MO,  USA). Heparan sulfate (HS, from bovine pancreas)
nd chondroitin sulfate lyases AC and B (from Flavobacterium hep-
rinum) were prepared by methods previously described (Aguiar,
ima, Berto, & Michelacci, 2003; Dietrich & Nader, 1974). Agarose
standard, low Mr), nitrocellulose and Zeta-Probe membranes were
urchased from Bio-Rad Laboratories (Richmond, CA, USA). MST1
nti-KS monoclonal antibody was obtained as previously describedlymers 134 (2015) 300–308 301
(Alves, Straus, Takahashi, & Michelacci, 1994). 2-Aminoacridone
(AMAC), mercuric acetate, sodium cyanoborohydride, glycine,
N,N,N′,N′-tetramethylenediamine (TEMED), and Dowex AG50W-
X8 (200–400 mesh) were purchased from Sigma–Aldrich Co.
Tetramethylbenzidine was from KPL (Gaithersburg, MD,  USA),
and SuperSignal West Pico chemoluminescent substrate was
from Thermo Scientiﬁc (Rockford, IL, USA). Standard unsatu-
rated disaccharides Di0S, Di2S, Di4S, and Di6S were from
Sigma–Aldrich Co., and standard Di2,6S, Di4,6S, Di2,4,6S
were from Seikagaku Kogyo Co. Ltd. (Tokyo, Japan). These disac-
charides were a kind gift from Prof. Dr. Mauro Pavão, UFRJ, Rio de
Janeiro, RJ, Brazil. Standard Di0S, Di4S, and Di6S were also
prepared by methods previously described (Michelacci & Dietrich,
1976).
2.2. Agarose gel electrophoresis of CS samples
All CS samples were submitted to agarose gel electrophoresis as
previously described (Dietrich & Dietrich, 1976). Brieﬂy, 1 mg/mL
solutions of CS samples were prepared, and aliquots (5 L) were
applied to agarose gel slabs in 0.05 M 1,3-diaminopropane-acetate
buffer, pH 9 (PDA). After ﬁxation with cetyltrimethylammonium
bromide (cetavlon) and Toluidine Blue staining, the glycosamino-
glycans were quantiﬁed by densitometry of the gel slabs (Epson
Expression 1680 Flatbed Scanner, with QuickScan Win  2000,
Helena Laboratories, Beaumont, TX, USA). Analysis was  per-
formed in triplicates, using Sigma–Aldrich chondroitin sulfate
as standard. These compounds were further characterized by
enzymatic degradation with bacterial glycosaminoglycan lyases
(chondroitinase AC and chondroitinase B from Flavobacterium
heparinum), as already described (Petricevich & Michelacci,
1990).
2.3. Analytical data
Aminosugars were determined after acid hydrolysis (4 M HCl
for 6 h at 100 ◦C) by a modiﬁed Elson–Morgan reaction (Rondle &
Morgan, 1955). Uronic acid was determined by a modiﬁcation of the
carbazole reaction (Di Ferrante et al., 1971). Total sulfate was mea-
sured by paper chromatography after acid hydrolysis (8 M HCl for
6 h at 100 ◦C), as previously described (Nader & Dietrich, 1977), and
soluble protein was  measured by a modiﬁed Lowry procedure with
bicinchoninic acid (BCA Protein Kit Assay, Pierce, IL, USA), using
bovine serum albumin as standard (Smith et al., 1985). Reducing
sugars were measured by the method of 3-5-dinitrosalicylic acid
(DNS, Miller, 1959).
2.4. Identiﬁcation of main contaminants of CS-poor samples by
FACE (ﬂuorophore-assisted carbohydrate electrophoresis) and
Raman spectroscopy
2.4.1. Treatment of unsaturated disaccharides with mercuric
acetate
Aliquots of standard unsaturated disaccharides (<50 nmol)
were frozen on dry ice, and lyophilized on a vacuum concen-
trator until dry. These samples were resuspended in 100 L of
17.5 mM mercuric acetate, 50 mM sodium acetate, and incubated at
room temperature (30 min, Calabro, Benavides, Tammi, Hascall, &through a glass wool plugged pipette tip. Both the reaction tube
and the glass wool were washed with 100 L of ultrapure water,
and the trapped volume was recovered by centrifugation
(2000 × g). The samples were again frozen and vacuum dried.
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.4.2. Fluorescent derivatization with 2-aminoacridone (AMAC)
The derivatization was performed as described by Calabro
t al. (2000), with modiﬁcations. Dried samples (20–200 nmol
f saccharides) were derivatized by addition of 5 L of 50 mM
MAC (250 nmol) in 85% DMSO/15% acetic acid. After 15 min
ncubation at room temperature, 5 L of a newly prepared
 M sodium cyanoborohydride solution was added, incubated
or 16 h at 37 ◦C, and then 30 L of 30% glycerol were added.
ne aliquot (2 L) of each derivatized sample was  immedi-
tely analyzed, and the remaining was stored in the dark at
80 ◦C.
.4.3. Fluorophore-assisted carbohydrate electrophoresis
Electrophoresis were carried out in Mini-Protean Tetra Cell (Bio-
ad Laboratories, Richmond, CA, USA) in two alternative buffer
ystems: nonborate buffer system (anionic oligosaccharides) and
orate-containing buffer system (for neutral sugars).
For nonborate conditions, gels were prepared in Tris–HCl buffer
nd run in Tris–glycine buffer. Polyacrylamide separating gels (20%)
ere prepared as described by Oonuki, Yoshida, Uchiyama, and
sari (2005), with some modiﬁcations. Acrylamide-bisacrylamide
tock solution (40% containing 5% bisacrylamide, 5 mL) plus 1.5 M
ris–HCl buffer, pH 8.9 (1.5 mL)  were diluted with 3.5 mL  of pure
ater. This solution was degased for a few minutes, and then
ixed with 0.1 mL  of 10% APS and 10 L of TEMED. The gel solu-
ion was poured into sets of glass boards with butanol added
o the top, and was left until completion of gelling. Then 0.5 mL
f the acrylamide–bisacrylamide solution (40%) was  mixed with
.66 mL  of 0.5 M Tris–HCl buffer (pH 6.7), and diluted with 3 mL  of
ure water. Also this “stacking gel solution” was  degassed. After
he butanol was taken away from the top of the separating gel,
 L of TEMED and 50 L of 10% APS were added to the stack-
ng gel solution, which was poured on top of the separation gel
nd a sample comb was set into the stacking gel. Stock electrode
uffer, 10× was 1.92 M glycine, 0.25 M Tris base, pH 8.3. The run
100–220 V, 70 min) was followed with the aid of an UV-lamp
320–400 nm).
For borate-containing conditions, the stock resolving gel buffer
× was 0.75 M Tris-0.5 M boric acid, adjusted to pH 7.0 with con-
entrated HCl; the stock stacking gel buffer, 4× was 0.5 M Tris-0.5 M
oric acid, adjusted to pH 6.8 with concentrated HCl, and the stock
lectrode buffer, 5× was 0.5 M glycine, 0.6 M Tris base, and 0.5 M
oric acid, ﬁnal pH 8.3 (Gao & Lehrman, 2003).
After electrophoresis, gels were removed from the apparatus,
lluminated with a UV transilluminator (365 nm), and photo-
raphed (GelDoc-It Imaging System, UVP). Quantitative results
ere obtained with TotalLab TL120 1D v2009 software, Nonlinear
ynamics Ltd.
.4.4. Raman spectroscopy
Fourier transform Raman measurements were carried out using
 Bruker RFS 100 instrument equipped with a Nd:YAG laser, a
ermanium detector cooled with liquid nitrogen, operating at
064 nm.  The in situ analysis of each solid sample was  obtained
ith 1000 scans collected at resolution of 4 cm−1, with a power of
5 mW.  These parameters were selected in order to obtain the best
ignal-to-noise ratio while the physical and chemical integrity of
he samples was maintained; this was achieved by repeating each
ne of the spectra and observing the possible changes in position
nd intensity over all the spectrum bands. The FT-Raman spec-
ra in the range of 3500–50 nm were obtained from the reference
tandard chondroitin 4-sulfate, maltodextrin, lactose, sodium sul-
ate, and sixteen pharmaceutical chondroitin sulfate samples. The
eak assignment was based on Bansil, Yannas, and Stanley (1978)
nd on Ellis, Green, and Winlove (2009).lymers 134 (2015) 300–308
2.5. Structural analysis of the CS of the “CS-rich”
Aliquots of CS samples (100 g, 10 L of 10 mg/mL  solutions)
were incubated with 10 mU of chondroitin lyase AC (10 L) in
0.05 M ethylenediamine-acetate (EDA) buffer, pH 8.0, at room tem-
perature. After 18 h incubation, aliquots (2 L) were submitted
to agarose gel electrophoresis as described in Section 2.2. The
remaining 18 L were applied to Whatman #1 ﬁlter paper and sub-
mitted to descending chromatography in isobutyric acid: 1.25 M
NH4OH, 5:3, v/v. After 24 h, the reducing products were located by
silver nitrate staining.
Alternatively, 20 g of substrate were incubated with 2 mU of
chondroitin lyase AC in EDA buffer, 50 L ﬁnal volume. After 18 h
incubation at room temperature, the samples were vacuum dried,
derivatized with AMAC as described in Section 2.4.2., and submitted
to FACE as in Section 2.4.3.
The molecular weight of the chondroitin sulfates was deter-
mined by polyacrylamide gel electrophoresis as previously
described (Dietrich & Nader, 1974; Hilborn & Anastassiadis, 1971).
2.6. Detection of keratan sulfate by immunoblotting
Keratan sulfate was  detected in the samples by immunoblotting
probed with MST1, a monoclonal antibody that recognizes ker-
atan sulfate both as free chains and as proteoglycans (Alves et al.,
1994; Baccarin et al., 2012; Pereira, Aguiar, Hagiwara, & Michelacci,
2004). After agarose gel electrophoresis, the glycosaminoglycans
were transferred to nitrocellulose and Zeta-Probe nylon mem-
branes. After blocking, membranes were probed with MST1. Then,
the membranes were incubated with peroxidase-conjugated rabbit
anti-mouse IgG secondary antibody, and either tetramethylben-
zidine (TMB) or SuperSignal West Pico was  used as substrates.
Quantitative analysis were performed by ELISA (Alves et al., 1994),
using keratan sulfate puriﬁed from bovine nucleus pulposus as
standard.
3. Results and discussion
3.1. Agarose gel electrophoresis of CS samples
Sixteen pharmaceutical grade CS samples were analyzed by
agarose gel electrophoresis in PDA buffer, in comparison to USP-CS
and analytical grade Ch4S. USP-CS contained less CS (96.4%) then
the analytical grade Ch4S. That is why  the analytical grade Ch4S
was used as standard in the following experiments. Fig. 1 shows
representative agarose gel slabs (B), as well as a standard curve
of Ch4S (A). The bands were quantiﬁed by densitometry, and the
curve was  linear (R2 = 0.9998) between 1 and 8 g of CS (European
Pharmacopoeia, 2007; United States Pharmacopoeia, 2008). For all
CS samples, a single band appeared, migrating as the standard Ch4S
(Fig. 1B). However, only ﬁve samples – #3, 4, 6, 12 and 16 – were
more than 90% CS (average 96.5%), while the remaining eleven were
less than 15% CS (average 10%) (Table 1). Thus, these samples were
classiﬁed as “CS-rich” (#3, 4, 6, 12 and 16) and “CS-poor” (#1, 2, 5,
7, 8, 9, 10, 11, 13, 14, 15) samples.
Electrophoretic techniques are recommended by both the Euro-
pean Pharmacopeia (agarose gel electrophoresis in barium acetate
buffer) and the United States Pharmacopeia (cellulose acetate elec-
trophoresis in barium acetate buffer) for CS analysis. Not more
than 2% of any individual impurity is acceptable. Furthermore, both
pharmacopeias describe a photometric titration procedure with
cetylpyridinium chloride (CPC), which forms insoluble complexes
with CS and precipitate. Nevertheless, this procedure is not speciﬁc,
since other glycosaminoglycans, nucleic acids, and even inorganic
salts interfere with the CS quantiﬁcation (Sim et al., 2005; Volpi,
A.L. Cunha et al. / Carbohydrate Polymers 134 (2015) 300–308 303
Fig. 1. Agarose gel electrophoresis of CS samples. (A) Calibration curve for CS. Standard chondroitin 4-sulfate (std CS) solutions were prepared: 0.2 mg/mL, 0.4 mg/mL,
0.8  mg/mL, 1.2 mg/mL, 1.6 mg/mL, and 5 L aliquots of each were applied to 0.55% agarose gel in 0.05 M 1,3-diaminopropane-acetate buffer, pH 9.0 (PDA). After the run,
the  glycosaminoglycans were precipitated in the gel by 0.1% cetyltrimethylammonium bromide (cetavlon), the gel was  dried, and stained by Toluidine Blue, as previously
described (Dietrich & Dietrich, 1976). CS was quantiﬁed by densitometry, and mean ± standard deviation for three independent determinations are shown. The curve was
linear  from 1 to 8 g of CS. A representative gel of the 16 CS samples here analyzed is shown in (B). Aqueous solutions (1 mg/mL) of each CS sample (1–16) were prepared, and
5  L aliquots were submitted to agarose gel electrophoresis as above described. CS was quantiﬁed by densitometry in comparison to standard CS run in the same gel, and also
to  the CS standard curve. Quantitative results are mean ± standard deviation of three independent determinations. M,  mixture of standard glycosaminoglycans containing
chondroitin sulfate (CS), dermatan sulfate (DS), and heparan sulfate (HS) (5 g each).
Table 1
Analytical data of sixteen samples of pharmaceutical grade CS.
CS CS content Protein Reducing sugars GlcUA GalNAc Sulfate
#  (%) (%) (g/100 g of sample) (g/100 g of sample) (g/100 g of sample) (g/100 g of sample)
CS-rich 3 91.0 3.6 8.3 38.2 33.4 27.3a
4 94.0 3.5 8.1 36.3 29.0 17.9a
6 97.8 1.9 9.0 37.5 32.0 29.3a
12 97.8 3.6 9.7 39.7 40.3 25.5a
16 102.0 3.5 9.2 36.8 33.7 24.6a
Mean ± SD 96.5 ± 4.2 3.2 ± 0.7 8.9 ± 0.7 37.7 ± 1.3 33.7 ± 4.1 24.9 ± 4.3
CS-poor 1 10.4 3.0 33.3 19.0 5.5 –
2  13.1 3.2 34.8 19.6 6.5 –
5  12.5 3.5 29.2 21.1 7.3 –
7  9.6 3.5 32.3 20.9 8.9 –
8  13.4 3.2 31.2 19.8 11.0 –
9  7.3 3.4 32.7 20.7 10.4 –
10  8.9 2.9 29.6 20.3 9.6 –
11  11.0 3.1 33.3 24.8 6.9 –
13  5.4 10.5 21.9 6.7 9.5 26.3b
14 11.4 3.1 32.4 23.6 11.8 –
15  6.8 11.1 19.8 7.9 8.0 26.1b
Mean ± SD 10.0 ± 2.7 4.6 ± 3.1 30.0 ± 4.9 18.6 ± 5.8 8.7 ± 2.0 26.2
Standards Ch4S 100.0 1.3 8.9 43.0 45.9 27.7a
Ch6S 100.0 0.0 7.5 42.0 39.5 24.0a
Maltodextrin – 3.4 35.4 17.7 3.3 –
Lactose – 9.1 54.5 14.1 3.3 –
Results are given as mean ± standard deviation.
a Sulfate detected only after acid hydrolysis (HCl 8 M,  6 h, 100 ◦C).
b Inorganic free sulfate.
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Fig. 2. Fluorophore-assisted carbohydrate electrophoresis (FACE) of CS samples in Tris-borate-glycine buffer. The CS samples were analyzed by FACE in 0.12 M Tris-borate-
glycine buffer, pH 8.3, in order to identify the main contaminants. CS samples (50 g) were derivatized with AMAC, and aliquots (2.5 g) were submitted to electrophoresis
as  described in Section 2.4. Gel images were obtained under UV ( = 365 nm)  with a scientiﬁc grade CCD Camera (GelDoc-It Imaging System, equipped with GelCam 310). For
comparison, maltodextrin was equally derivatized with AMAC and analyzed by FACE, under the same conditions. A band patter similar to that of maltodextrin was observed
in  CS samples 1, 2, 5, 7, 8, 9, 10, 11 and 14, but did not appear in the CS-rich samples (3, 4, 6, 12 and 16), as well as in samples 13 and 15, which presented only one band
(arrow).
Fig. 3. Acid hydrolysis of CS-poor samples. To further characterize the main contaminants of CS-poor samples (15% CS or less), aliquots (20 g) were submitted to acid
hydrolysis (6 M HCl, 100 ◦C, 6 h), and then derivatized by AMAC and analyzed by FACE, under the same conditions described in Fig. 2. For comparison, maltodextrin was
equally  submitted to acid hydrolysis, treated with AMAC and analyzed by FACE, under the same conditions. Now, the electroﬂuorogram showed a single band for samples 1,
2,  5, 7, 8, 9, 10, 11, 14 and maltodextrin, migrating as glucose (Glc) (A). In contrast, for samples 13 and 15, which have shown only one band, migrating as lactose (Lac) before
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aydrolysis, two  bands appeared after acid hydrolysis, migrating as glucose (Glc) an
007). For instance, it was recently shown that propylene glycol
lginate sulfate sodium, also known as alginic sodium diester (ASD),
nd Zero One (Z1), a water-soluble agent recently identiﬁed as
odium hexametaphosphate, are also titratable anions and form
onic pairs with CPC, therefore interfering with the CPC titration
Weiguo et al., 2014). The authors suggest that CPC titration and
lectrophoresis to be used in combination to detect CS adulterants
SD and Z1.
The agarose gel electrophoresis here used, developed by Jaques,
allieux, Dietrich, and Kavanagh (1968) and modiﬁed by Dietrich
nd Dietrich (1976), using a special buffer system – PDA – to permit
he separation and identiﬁcation of different glycosaminoglycans,
s much more precise and speciﬁc. After electrophoresis, the gly-
osaminoglycans are precipitated in the gel by a cationic detergent
cetavlon), the gel is dried under a sheet of paper and hot air ﬂow to
emove excess cetavlon and buffer, and stained by Toluidine Blue.
nly metachromatic bands are glycosaminoglycans. These bands
re quantiﬁed by densitometry.ctose (Gal) (B). Gel images were obtained as described in Fig. 2.
3.2. Analytical data
Table 1 shows the analytical data of our CS samples, and
standards Ch4S, Ch6S, maltodextrin and lactose. Only two of the
CS-poor samples – #13 and 15 – contained signiﬁcant amounts of
soluble proteins (∼10%). All other samples contained ∼3% protein.
In contrast, all the “CS-poor” samples contained much more reduc-
ing sugars than the “CS-rich” samples (about 3 times), while the
amounts of glucuronic acid (GlcUA) and galactosamine (GalNAc)
were lower (a half for GlcUA, and one third for GalNAc). These
results are in agreement with the ﬁndings shown in Fig. 1. It is also
important to notice that the GlcUA measurement may be overesti-
mated in some “CS-poor” samples due to the possible presence of
neutral sugars (see Table 1 and Section 3.3). Free inorganic sulfate
was also detected only in samples #13 and 15 (before acid hydroly-
sis). In the “CS-rich” samples, as well as in standard Ch4S and Ch6S,
sulfate was measured after acid hydrolysis of the polymers (HCl
8 M,  6 h, 100 ◦C).
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Fig. 4. Raman spectra of CS pharmaceutical samples and standards. In situ analysis of reference standards and representative samples by macro-Raman spectroscopy operating
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.3. Identiﬁcation of main contaminants of CS-poor samples by
ACE and Raman spectroscopy
As CS was only a minor component of 11 (out of 16) CS sam-
les, corresponding to only 5–13% of total weight, we decided to
nvestigate the main contaminants. So, the “CS-poor” samples were
ubmitted to FACE in Tris-borate-glycine buffer system (Fig. 2). In
, out of these 11 “CS-poor” samples – #1, 2, 5, 7–11, 14 – several
ands appeared. These bands migrated as those obtained from mal-
odextrin (Fig. 2). The remaining two “CS-poor” samples – #13 and
5 – presented a single intense band (arrow, Fig. 2). In the “CS-rich”
amples, no bands appeared.
In order to further characterize the contaminant carbohydrates,
he “CS-poor” samples were again submitted to acid hydrolysis
HCl 6 M,  6 h, 100 ◦C), and analyzed by FACE in Tris-borate-glycine
uffer system (Fig. 3). A single band migrating as glucose was
bserved in all samples that presented the “maltodextrin-type”
and pattern – #1, 2, 5, 7-11, 14, Fig. 3A. In contrast, the “CS-poor”
amples that presented only one intense band in Fig. 2, exhibited,
fter acid hydrolysis, two bands of the same intensity, migrat-
ng as glucose and galactose (Fig. 3B). Actually, the single band
bserved in the non-hydrolyzed material had the same migration of
actose.ands are shown in the region of 1800–200 cm .
These results were conﬁrmed by Raman spectroscopy. Fig. 4
shows representative spectra of standard CS, maltodextrin, lactose,
and sodium sulfate, as well as selected CS samples (#12, 13, and 14).
The main component of CS #12 presents a Raman proﬁle similar to
that of standard CS, while the spectrum of sample #14 is similar to
that of maltodextrin, and the sample #13 spectrum resembles that
of lactose and sodium sulfate.
So, our data show that the main contaminant of samples #1, 2, 5,
7–11, and 14 was maltodextrin, while samples #13 and 15 contain
predominantly lactose (51% and 46%, respectively), sulfate (∼26%),
and protein (∼10%), with only 5–6% CS. This ﬁnding is alarming
since medicines prepared from these raw materials will not only
contain much less of the desired active principle (CS), but also could
have serious side effects from the contaminants.
Unconformities regarding CS content in nutraceuticals, as well
as the presence of other contaminant sugars and glycosaminogly-
cans have also been reported by others (Adebowale, Cox, Liang, &
Eddington, 2000; Sim et al., 2005; Volpi, 2009).
To our knowledge, this is the ﬁrst study to describe phar-
maceutical preparations having less than 15% CS, and in which
the main contaminants of eleven preparations were totally char-
acterized. It is still important to note that these contaminants
could not be impurities from the extraction and puriﬁcation
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Fig. 5. FACE (Tris-glycine buffer), and PAGE of the ﬁve “CS-rich” samples. To access the CS sulfation pattern and modal molecular weight, the “CS-rich” samples were further
analyzed by FACE after enzymatic degradation, and by PAGE. Aliquots (20 g) of each sample were incubated with Flavobacterium heparinum chondroitin lyase AC (2 mU). The
products formed were derivatized with AMAC, and analyzed by FACE in 0.025 M Tris-glycine buffer, pH 8.3. Gel images were obtained as described in Fig. 2. A representative gel
is  shown in (A). The bands were quantiﬁed by densitometry using TotalLab TL120 software. Two independent derivatizations were made for each sample, and three gels were
run  for each derivatization. For the determination of CS modal molecular weight, aliquots (10 g) of CS samples were applied to a 7.5% polyacrylamide gel in 20 mM Tris-HCl
buffer,  pH 7.4, as previously described (Hilborn & Anastassiadis, 1971; Dietrich & Nader, 1974). After the run (100 V, 50 min) the gels were stained with 0.1% Toluidine Blue
in  1% acetic acid (B), and analyzed by densitometry. Di0S, 2-acetamido-2-deoxy-3-O-(-d-gluco-4-enepyranosyluronic acid)-d-galactose; Di6S, 2-acetamido-2-deoxy-
3 mido-2-deoxy-3-O-(-d-gluco-4-enepyranosyluronic acid)-4-O-sulfo-d-galactose; Tetra,
t CS extracted from bovine trachea (Sigma–Aldrich); Ch6S, standard CS from shark cartilage
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Table 2
Disaccharide composition and molecular weight analysis of 5 pharmaceutical CS
samples with CS content above 90%.
Disaccharide composition Modal molecular
weight (kDa)
Di0S Di6S Di4S 4S/6S SO3/UA
Ch4S (standard) 10% 49% 41% 0.8 0.90 25.4
CS  sample #3 12% 33% 55% 1.7 0.88 27.6
CS  sample #4 13% 34% 53% 1.6 0.87 29.0
CS  sample #6 11% 47% 42% 0.9 0.89 24.0
CS  sample #12 9% 44% 47% 1.1 0.91 19.6
CS  sample #16 10% 44% 46% 1.0 0.90 20.4
F
e
e
S
s
(-O-(-d-gluco-4-enepyranosyluronic acid)-6-O-sulfo-d-galactose; Di4S, 2-aceta
etrasaccharides; M,  mixture of standard unsaturated disaccharides; Ch4S, standard 
Sigma–Aldrich); 3, 4, 6, 12 and 16, CS pharmaceutical samples.
rocedures, since they are not found in the same animal sources of
S.
.4. Structural analysis of the CS of the “CS-rich”
Standard disaccharides were characterized by FACE, and also
y treatment with mercuric acetate, followed by FACE (nonborate
ystem). The products formed from the “CS-rich” samples were
ompared to these standards.
Aliquots (20 g) of the “CS-rich” samples – #3, 4, 6, 12, 16 –
ere incubated with F. heparinum chondroitin lyase AC as describedn Section 2.5, and derivatized with AMAC (40 L ﬁnal volume).
liquots (2 L, containing ∼1 g of CS products) were submitted
o FACE, as described in Section 2.4.3. Representative results are
hown in Fig. 5, and quantitative data are given in Table 2. All the
ig. 6. Immunoblotting of keratan sulfate. Aliquots (5 g) of the ﬁve CS-rich samples (3, 4
xcept  that after the run the glycosaminoglycans were transferred to nitrocellulose mem
t  al., 1994). The blotting was  processed as previously described (Pereira et al., 2004). T
econdary antibody conjugated with horseradish peroxidase (HRP) was  used, and two s
trate  (A), and tetramethylbenzidine (TMB) (B). KS std 1, standard keratan sulfate prote
Sigma–Aldrich)., 6, 12 and 16) were submitted to agarose gel electrophoresis as described in Fig. 1,
brane, and revealed by an anti-keratan sulfate monoclonal antibody – MST1 (Alves
his antibody recognizes keratan sulfate both as free chains and as proteoglycans.
ubstrates were used in sequence: Super Signal West Pico chemiluminescent sub-
oglycan; KS std 2, standard keratan sulfate; Ch4S, standard chondroitin 4-sulfate
ate Po
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S samples gave three bands migrating as Di0S, Di4S, Di6S,
nd trace amounts of tetrasaccharide (Tetra). Nevertheless, the rel-
tive proportions of disaccharides varied. All of them contained
10% Di0S, but samples #3 and 4 contained predominantly Di4S
Di4S:Di6S ratios 1.6–1.7), while samples #6, 12, and 16 contained
imilar amounts of Di4S and Di6S (Di4S:Di6S ratios 0.9–1.1). Fig. 5
lso shows a polyacrylamide gel electrophoresis of the same sam-
les, performed to determine the molecular weight of the polymers.
ll of them were polydisperse polymers, with modal molecular
eight ∼20 kDa.
Differences in the composition and biological activities of
hondroitin sulfates of different origins were also reported by oth-
rs (Martel-Pelletier, Farran, Montell, Vergés, & Pelletier, 2015;
ichelacci & Dietrich, 1976; Michelacci et al., 1979).
.5. Detection of keratan sulfate by immunoblotting
Although only one band migrating as CS was observed for all “CS-
ich” samples in agarose gel electrophoresis (Fig. 1), trace amounts
f keratan sulfate appeared on immunoblotting probed with mono-
lonal antibody (MST1) (Fig. 6). The identiﬁcation of keratan sulfate
as conﬁrmed by incubation with Pseudomonas sp. keratanase.
uantitative analysis performed by ELISA using the same primary
ntibody has shown that keratan sulfate corresponds to less than
% of total glycosaminoglycan of these samples. It is important to
otice that even the standard Ch4S (Sigma–Aldrich) also contained
race amounts of keratan sulfate. This keratan sulfate probably
omes from the same biological source – cartilage – and due to
ts polyanionic nature was not separated from chondroitin sulfate
uring the puriﬁcation procedures.
The presence of keratan sulfate in CS preparations was  also
ecently reported by others (Nakano & Ozimek, 2014).
. Conclusions
In conclusion, our data show that, out of 16 CS samples pre-
ared in different countries all over the world, only 5 contained
ore than 90% CS and were in conformity to their labels. The
emaining 11 CS-poor samples contained maltodextrin or lactose
s the main contaminants (both of which are commonly used as
harmaceutical excipients). It is important to reinforce that these
CS” preparations came from diverse locations, and all of them are
learly not in conformity to their label speciﬁcations.
This ﬁnding could explain, at least in part, the variations
eported by different authors in the biological responses of
steoarthritis to CS treatment. In addition, some contaminants
ould lead to serious side effects, especially in sensible patients
for instance, lactose in intolerant patients).
We strongly suggest that more efﬁcient and strict criteria should
e applied to both licensing and quality control of raw materials,
s well as to the ﬁnal pharmacological preparations obtained from
hem.
The use of agarose gel electrophoresis, as well as FACE and
aman spectroscopy, to determine both the CS contents and
he eventual presence/identiﬁcation of contaminants, is recom-
ended.
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